VEGFA and neoplasm: In LLC and B16 tumours, loss of VEGF-A in myeloid cells significantly increased tumour-doubling time (Fig. 1b for LLC and Fig. 1c for B16) and was associated with significantly reduced endpoint tumour volumes (Fig. 1d,f for LLC and Fig. 1e,g for B16).